Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Thursday, May 7, 2026

Snapshot: May 7, 2026 · 6:00 PM 100 stocks analyzed

Down Day

Thu, May 7, 2026 Broad Selloff Extreme

Broad selloff hit small caps hardest as extreme dispersion saw 50+ stocks crater while earnings surprises—both beats and misses—triggered wild single-stock swings in a market br…

60% Small-cap washout dominated the day as Russell 2000 plunged 1.63% versus the S&P's 0.38% decline, with extreme dispersion sending 50 losers down an average 29.5% while 50 gainers soared 265.5%, marking a bifurcated market where individual stock selection utterly dwarfed index moves. Technology led losers at 29% of the decline, while catastrophic stock-specific collapses—GDC down 87.8%, ENGN down 80.6%, ONEG down 80.3%—overshadowed steadier large-cap weakness.
25% Earnings beat the tape but investors punished misses viciously: winners like AGL (+117.8%), ATRA (+92.8%), and RXT (+55%) celebrated guidance raises and AI partnerships, while PLNT (-31%), SHAK (-28%), ZTS (-21.5%), and FSLY (-38.3%) crashed on disappointing top-line or forward outlook despite some beating estimates, reflecting zero tolerance for guidance cuts or margin compression.
15% Five debutant names—AGL, ATRA, GLE, OSG, FLNC—returned to the gainers list after long absences, signaling tactical rotation into reopened value pockets and earnings-driven trades, while VIX barely budged at 17.08 (-1.8%), keeping volatility expectations muted despite the extreme single-stock dispersion.

Strongest avg gainer % YTD (265.5%) Worst avg loser % YTD (-29.5%) Biggest single-stock move YTD: CHSN +11630.8% Technology drove 50% of gainers 5 names returned after long absences AGL — first appearance

Market Regime

Thu, May 7, 2026 Risk-On conf: high macro · prototype

+38

Tailwind −100 … +100 · + tailwind / − headwind

VIX17.1 p46 Drawdown-0.4% Held19d · extended SinceApr 13

Top drivers: S&P 20d return ▲ S&P vs 50d avg ▲ S&P vs 20d avg ▲

processId: history-market-regime

Market Indexes

Thu, May 7, 2026 4

S&P 500

7,337.11

−28.01

-0.38%

NASDAQ Composite

25,806.20

−32.75

-0.13%

Russell 2000

2,839.63

−47.15

-1.63%

VIX

17.08

−0.31

-1.78%

Biggest Gainers

Thu, May 7, 2026 50

CHSN

Chanson International HoldingConsumer Cyclical

$1.83+$1.81

+11,630.8%

NASDAQ · Mkt cap $2.6 M

Chanson International announced an AI-driven intelligent manufacturing strategy on May 7, 2026, but an 11,630% single-day gain is extraordinarily large and suggests either a reverse stock split, a delisting reversal, or an undisclosed capital event rather than organic market reaction to the opera…

The provided headline describes Chanson advancing a growth strategy through AI-driven intelligent manufacturing and industrial upgrades. This is a standard corporate development announcement typical of manufacturing and consumer goods companies pivoting toward automation and efficiency. Such announcements rarely trigger five-figure percentage gains in a single day on major exchanges. The extreme magnitude of the price move—ranking 1 biggest gainer—suggests a structural corporate event occurred that is not explained by the headline text provided. Possible categories include a reverse stock split adjustment, correction of a prior delisting or suspension, a major capital restructuring, or a significant undisclosed announcement not captured in the 48-hour news window. The strategy itself, while positive, does not account for this scale of gain through normal fundamental reassessment.

AGL

Agilon Health, Inc.Healthcare

$60.65+$32.80

+117.8%

NYSE · Mkt cap $1.5 B

Agilon Health surged 117.76% after reporting Q1 2026 earnings that substantially beat guidance across revenue, medical margin, and adjusted EBITDA, with management raising full-year expectations following a difficult 2025.

The stock's move is grounded in a clear earnings catalyst. Agilon reported Q1 results exceeding its own guidance ranges on total revenue, medical margin, and adjusted EBITDA, with a headline earnings surprise of +58.73% and revenue surprise of +3.28%. Most critically, management raised full-year 2026 guidance following these results, a reversal from the company's troubled 2025 when shares cratered due to financial underperformance and a guidance suspension. The combination of a substantial beat on profitability metrics (margin and EBITDA are closely watched in healthcare services) plus raised forward guidance represents a material inflection for investor sentiment. The stock was already up 27.9% immediately after earnings release on May 6, and continued higher on May 7, suggesting sustained momentum as investors repriced the turnaround narrative.

ATRA

Atara Biotherapeutics, Inc.Healthcare

$9.93+$4.78

+92.8%

NASDAQ · Mkt cap $75 M

Atara Biotherapeutics surged nearly 93% after the FDA outlined a potential regulatory pathway for resubmitting its tabelecleucel application following a Complete Response Letter, reviving hopes for the drug candidate's approval timeline.

On May 7, 2026, Atara announced that the FDA provided guidance on how the company could resubmit its tabelecleucel application after receiving a Complete Response Letter, which typically signals rejection but allows for resubmission with additional data or modifications. The market interpreted this FDA feedback as constructive and a lifeline for the program rather than a dead end. For a biotech company with a lead candidate in regulatory limbo, receiving a clear resubmission pathway is materially positive because it preserves the commercial opportunity and gives investors a concrete next step. The stock's +92.82% jump reflects relief and renewed confidence that tabelecleucel remains viable, likely after prior concerns that the CRL was fatal to the program. This is classic binary-outcome biotech behavior where regulatory clarity—even if not outright approval—can trigger large repricing.

SOBR

SOBR Safe, Inc.Technology

$1.80+$0.77

+74.8%

NASDAQ · Mkt cap $1.6 M

No news headlines were found in the last 48 hours, so the 74.76% gain cannot be attributed to a publicly reported catalyst. The jump likely stems from technical buying, retail interest, or delayed reaction to an earlier announcement.

SOBR Safe, Inc. posted a remarkable one-day gain of nearly 75% with no corresponding news coverage in the immediate timeframe. This disconnect suggests either that the catalyst predates the 48-hour window provided, that the move is driven by technical factors or sentiment rather than fundamental news, or that a material announcement has not yet been widely indexed by financial news aggregators. Micro-cap and penny stocks like SOBR are prone to sharp moves on low volume, short covering, or renewed retail attention following prior events. Without access to earlier news or intraday trading data, we cannot pinpoint the specific trigger, though for a safety-focused company this type of jump could theoretically relate to contract wins, regulatory approvals, or investor presentations.

RPGL

Republic Power Group Limited Class A Ordinary SharesTechnology

$2.30+$0.97

+72.9%

NASDAQ · Mkt cap $2.6 M

No news headlines were found in the last 48 hours, so the 72.93% jump cannot be attributed to any reported company announcement or market catalyst covered by major outlets.

Republic Power Group Limited experienced a substantial one-day gain of nearly 73 percent without any corresponding news coverage detected in the Yahoo Finance RSS feed over the preceding two days. This absence of reported headlines makes direct causation impossible to establish. For a small-cap or micro-cap stock like RPGL trading at $2.30, typical catalysts for such moves include technical rebounds after heavy selling, short squeeze activity, sector rotation tailwinds, private news flow not yet reported by major outlets, or retail trading momentum. Given the stock's rank as the fifth-largest gainer of the day, it may reflect broader market conditions favoring a particular sector or market microstructure effects rather than company-specific fundamentals.

RXT

Rackspace Technology, Inc.Technology

$3.52+$1.25

+55.1%

NASDAQ · Mkt cap $839 M

Rackspace stock surged 55% on the strength of a multiyear strategic partnership with AMD announced this morning to develop AI infrastructure for regulated industries, overshadowing an otherwise modest earnings report.

Rackspace released Q1 2026 results showing modest growth (2% YoY revenue to $678 million) with mixed segment performance—private cloud down 6% but public cloud up 7%. However, the headline catalyst was the same-day announcement of a strategic collaboration with AMD (a major chip designer) to build a new category of governed enterprise AI infrastructure for mission-critical workloads in regulated sectors. The market clearly interpreted this partnership as a significant strategic pivot toward high-growth AI opportunities, more than offsetting the lukewarm underlying business metrics. One headline explicitly stated the AMD partnership "stole the show" from the earnings report itself, suggesting investors view this deal as a major inflection point for the company's relevance in the AI infrastructure arms race.

GLE

Global Engine Group Holding Limited Ordinary SharesTechnology

$0.55+$0.19

+52.1%

NASDAQ · Mkt cap $6.8 M

Global Engine Group announced a memorandum of understanding with Angkasa-X Holdings to integrate satellite networks, blockchain, and AI infrastructure, catalyzing a 52% single-day rally likely driven by investor enthusiasm for the emerging AI and space-tech angle.

The headline, released on 2026-05-06 at 20:15 UTC, describes a strategic MOU between GLE and Angkasa-X Holdings focused on combining satellite networks, data infrastructure, and blockchain technology to support artificial intelligence applications. This is a forward-looking partnership announcement rather than a finalized acquisition or contract with near-term revenue impact. The rally suggests investors reacted positively to the strategic positioning in high-growth sectors: satellite communications, blockchain, and AI infrastructure. However, an MOU is exploratory and non-binding, so the announcement carries more symbolic and sentiment value than concrete commercial commitment. The 52% one-day jump is outsized relative to typical MOU news for established firms, suggesting either the market was pricing in significant prior pessimism, the stock has low liquidity and high volatility, or there is broader momentum in the small-cap tech space on this date.

AMPGZ

Amplitech Group, Inc. Series B Right

$0.08+$0.02

+49.7%

NASDAQ

No news headlines were found in the last 48 hours, so the 49.70% gain in AMPGZ (a Series B Right offering) likely reflects either a technical rebound in a thinly traded security, a delayed market reaction to an earlier announcement, or movement in the underlying Amplitech equity.

The absence of any news in the last 48 hours makes it impossible to point to a specific catalyst for today's move. AMPGZ is a Series B Right, a derivative security tied to Amplitech Group that typically trades with very low liquidity and high volatility. Movements in rights offerings can be driven by several factors unrelated to contemporaneous headlines: shifts in the price of the underlying common stock, technical bounces from oversold conditions, options expiration mechanics, or reactions to news about Amplitech itself that may not be separately indexed as headline stories about the right itself. Without visibility into Amplitech's own price action today or any corporate announcements, the most honest assessment is that the cause remains unclear from the available evidence.

BNZI

Banzai International, Inc.Technology

$0.32+$0.10

+44.7%

NASDAQ · Mkt cap $5.6 M

Banzai announced a reverse stock split on May 6, which likely triggered the 44.71% single-day gain as the stock price was mechanically adjusted upward to reflect the consolidation of shares.

Reverse stock splits are mechanical corporate actions that consolidate multiple existing shares into fewer shares at a higher per-share price. If Banzai announced a reverse split on May 6, the stock price would naturally jump the following trading day to reflect the new consolidated share count. For example, a 1-for-10 reverse split would move a $0.032 stock to approximately $0.32, matching the observed price. This is not a gain in market capitalization or shareholder value but rather a mathematical restatement of the share price. Reverse splits are often used by companies trading below exchange minimum price thresholds to maintain listing compliance. The headline confirms the announcement occurred but does not specify the split ratio, which would be needed to verify the exact price mechanics.

OSG

Octave Specialty Group, Inc.Financial Services

$6.05+$1.83

+43.4%

NYSE · Mkt cap $208 M

Octave Specialty Group reported first quarter 2026 results on May 6, triggering a 43% rally, likely driven by better-than-expected earnings or guidance that reassured investors after prior weakness in the specialty medical sector.

The stock jumped 43% the day after the company released Q1 2026 earnings on May 6. The headlines provided do not include the actual earnings details, beat/miss metrics, or any guidance revision, so the specific financial results cannot be verified from the available data. However, the timing strongly suggests the earnings announcement was the catalyst. The other two news items concern different companies (Alphatec and Select Medical) in adjacent healthcare niches and do not directly reference OSG. It is worth noting that the broader specialty medical and healthcare services space has shown volatility, with some peers reporting weakness; an OSG beat or raised outlook could have stood out as positive relative to recent sector underperformance. Without access to the actual earnings numbers, revenue, profitability, or forward guidance disclosed in the May 6 report, the specific reason for investor enthusiasm cannot be pinpointed.

FLNC

Fluence Energy, Inc.Utilities

$18.97+$5.41

+39.9%

NASDAQ · Mkt cap $1.9 B

Fluence Energy surged 39.9% after reporting Q2 2026 earnings featuring a record backlog, strong hyperscaler data center orders, and an earnings beat, despite missing revenue estimates.

Fluence reported mixed results on May 6 after market close: revenue fell 28.5% below analyst expectations, but earnings per share beat by 12.71%. The critical driver of the rally appears to be qualitative factors that overshadowed the revenue miss. Multiple headlines highlight accelerating order intake, record backlog levels, and notably strong traction with hyperscaler data center customers. The company also reaffirmed its full-year 2026 guidance. For an energy storage and software provider, a record backlog signals robust future revenue visibility and strong demand momentum in the high-growth data center power storage market. This forward-looking strength evidently resonated more with investors than the quarterly revenue shortfall, suggesting the market views the backlog and customer pipeline as more strategically important than near-term sales figures.

XMTR

Xometry, Inc.Industrials

$78.50+$22.10

+39.2%

NASDAQ · Mkt cap $5.3 B

Xometry surged 39% on a combination of record Q1 earnings that beat estimates by 84%, raised full-year guidance, accelerating 40% marketplace revenue growth, and a major strategic partnership with Siemens involving a $50 million investment.

The stock's jump is grounded in multiple positive catalysts announced on the same day. Xometry reported record Q1 2026 revenue of $205 million, up 36% year-over-year, with marketplace revenue accelerating at 40% growth. The company delivered an earnings surprise of 84.62% and a revenue surprise of 9.04%, and raised full-year expectations. The headline driver, however, was the announced strategic partnership with Siemens, wherein Siemens is investing $50 million in Xometry and embedding its AI-native manufacturability and sourcing tools into Siemens' Xcelerator platform. This combination of strong quarterly performance, improved profitability, raised guidance, and validation through a major enterprise partnership with a global manufacturing leader created a confluence of bullish signals that collectively justified the large single-day gain.

APT

Alpha Pro Tech, Ltd.Industrials

$6.48+$1.78

+37.9%

AMEX · Mkt cap $55 M

Alpha Pro Tech announced Q1 2026 results showing net sales of $14.6 million, a 5.5% year-over-year increase, which appears to have driven the 37.87% single-day jump on positive earnings momentum.

The company released first quarter 2026 financial results on May 7, 2026, showing net sales increased 5.5% to $14.6 million compared to $13.8 million in Q1 2025. This marks a positive earnings announcement with year-over-year growth. However, the headline excerpt provided does not include profitability metrics, margin data, guidance commentary, or management outlook that would typically accompany an earnings release and explain such a substantial 37.87% single-day move. A 5.5% sales growth alone may not fully justify this magnitude of price appreciation unless the market was pricing in a decline or the stock had been significantly depressed prior. The earnings announcement appears to be the most plausible catalyst, but without full earnings details, guidance revisions, or context on prior expectations, we cannot definitively attribute the entire move to fundamentals rather than market sentiment or technical factors.

RMSG

Real Messenger CorporationTechnology

$1.79+$0.47

+35.6%

NASDAQ · Mkt cap $5.4 M

Real Messenger announced it has regained compliance with Nasdaq's minimum bid price requirement, eliminating delisting risk and triggering a 35.61% rally as the stock recovers from penny-stock territory.

The headline directly addresses a critical compliance issue for RMSG. Stocks trading below $1.00 face automatic delisting from Nasdaq unless they cure the violation within a specified period. By announcing regained compliance, Real Messenger has removed existential regulatory risk that likely weighed heavily on the stock price. Investors previously holding or considering positions would view this announcement as a major de-risking event. The magnitude of the move, placing it 14th among daily gainers, reflects the outsized impact of delisting risk relief on micro-cap stocks. This is a pure binary event: either the company cures the violation or faces removal from the exchange, so the announcement's clarity creates a discrete positive catalyst.

SNES

SenesTech, Inc.Basic Materials

$1.97+$0.50

+34.0%

NASDAQ · Mkt cap $6.7 M

SenesTech announced the appointment of Michael Edell as President and CEO on May 7, likely triggering investor optimism about revenue growth and operational execution in the rodent birth control market.

On May 7, 2026, SenesTech announced a new CEO appointment effective May 6, positioning Michael Edell to drive revenue growth and scalable sales channels. This is a classic catalyst for small-cap stocks: C-suite leadership changes are often interpreted as signals of strategic repositioning, operational improvement, and potential acceleration in sales execution. The stock jumped 34% the same day the appointment was announced. Additionally, the company notified investors it will report Q1 2026 results on May 12, which creates near-term attention and may have amplified the bullish sentiment around the leadership transition. For a micro-cap company in the specialized pest control space, a credible new CEO with a growth mandate can shift investor perception materially, especially if prior leadership was seen as lacking commercial traction. The timing of both announcements on the same day suggests coordinated messaging.

LIFE

Ethos Technologies Inc.Financial Services

$30.59+$7.47

+32.3%

NASDAQ · Mkt cap $3.6 B

Ethos Technologies reported exceptional Q1 2026 results with 104% revenue growth, positive adjusted EBITDA, and strong direct channel performance, triggering the 32% rally on May 6-7.

The earnings release and call transcript released on May 6 evening disclosed Q1 revenue of $193 million, representing 104% year-over-year growth, with direct channel revenue surging 136% and third-party revenue growing 42%. CEO Peter Colis characterized the quarter as exceptional, and the company reported positive adjusted EBITDA, a profitability milestone for a high-growth company. These fundamentals—triple-digit topline growth coupled with margin expansion—are exactly the combination that typically drives sharp single-day rallies in growth stocks. The timing of the pre-market news release and evening earnings call allowed the market to process and price in the results on May 7, generating the 32% gain that made LIFE the 16th biggest gainer of the day.

AAON

AAON, Inc.Industrials

$129.25+$30.95

+31.5%

NASDAQ · Mkt cap $6.2 B

AAON reported record Q1 2026 sales of $496.9 million (up 54.3% YoY), crushed earnings estimates by 53%, and raised full-year guidance, driven by surging data center cooling demand and capacity investments paying off operationally.

AAON's earnings release on May 7 delivered a confluence of positive catalysts that explain the 31.49% gain. The company reported record quarterly sales with a 54.3% year-over-year increase, non-GAAP earnings that beat analyst expectations by more than 50%, and 37% earnings growth. Management highlighted record backlog and noted that deliberate organizational and capacity investments begun earlier are now translating into tangible operational leverage. The data center cooling equipment segment emerged as a key growth driver, with multiple headlines specifically calling out surging data center demand as a major contributor. The company also raised its full-year 2026 guidance, which typically signals management confidence in sustained momentum. These are textbook earnings beat fundamentals: revenue surprise, margin expansion, forward guidance lift, and a structural growth tailwind in a hot sector.

DDOG

Datadog, Inc.Technology

$188.73+$45.02

+31.3%

NASDAQ · Mkt cap $83 B

Datadog reported Q1 2026 earnings that beat expectations and raised full-year guidance, triggering a 31% surge. The results underscored strong demand for observability and AI-driven monitoring, prompting analyst price-target increases.

The news coverage establishes that Datadog released first-quarter results on May 7, 2026 that exceeded Wall Street estimates on both earnings and revenue, accompanied by raised full-year guidance. Multiple sources confirm the company posted adjusted earnings of 60 cents per share and highlighted robust demand powered by AI. Wedbush responded by lifting its price target on the stock. The earnings beat, forward guidance raise, and analyst upgrades represent the clearest catalysts for a 31% single-day move. Secondary headlines note that Snowflake stock rallied on the strength of Datadog's results, suggesting the market interpreted the earnings call as validating broader demand trends in cloud monitoring and observability services. The timing on earnings day, combined with consistent messaging across multiple outlets about beat-and-raise dynamics, makes this straightforward causation rather than inference.

HAWK

HawkEye 360, Inc.Industrials

$34.00+$8.00

+30.8%

NYSE · Mkt cap $1.7 B

HawkEye 360 completed its IPO on May 7, 2026, pricing at $26 per share and raising $416 million. The stock jumped 31% on its first day of trading, reflecting strong investor demand for satellite-based intelligence services in the space sector.

The headlines establish that HawkEye 360 priced its initial public offering at $26 on Wednesday and opened for trading on May 7, climbing approximately 31% from that IPO price to close near $34. This is a classic IPO pop, where a newly listed company's stock surges on its debut as pent-up demand from investors meets a limited float. The company provides satellite-based signals intelligence for U.S. government agencies, positioning it within the broader space economy trend. The headlines note that space stocks are currently experiencing investor enthusiasm ahead of other major space-sector IPOs. IPO pops of this magnitude are common when demand outpaces supply on day one, though they do not necessarily predict long-term performance. The fact that the stock priced at the top of its marketed range further suggests strong underwriter confidence and investor appetite.

HIMX

Himax Technologies, Inc.Technology

$16.03+$3.70

+30.0%

NASDAQ · Mkt cap $2.7 B

Himax beat Q1 revenue expectations and raised Q2 guidance to 10-13% sequential growth, driven by automotive, AI chip, and smart glasses momentum, triggering a 30% intraday rally.

On May 7, 2026, Himax reported Q1 results that exceeded market revenue expectations and posted earnings per share above its guidance range, with both revenue and gross margin at the high end of prior guidance. More importantly, the company provided Q2 2026 guidance calling for 10-13% sequential revenue growth, attributed to strength in automotive projects, non-driver ICs, WiseEye AI products, and smart glasses opportunities. This forward-looking confidence, combined with the beat in the current quarter, appears to have triggered a strong buy reaction. The stock hit $17.88 intraday (45% higher) before settling at $16.03 (+30.01%), placing it among the day's top gainers. The company also declared a cash dividend of 25.2 cents per ADS, though this is a routine shareholder return rather than a catalyst for the move. The rally reflects investor confidence in Himax's exposure to growth verticals in AI and automotive semiconductors.

CCRN

Cross Country Healthcare, Inc.Healthcare

$13.09+$2.98

+29.5%

NASDAQ · Mkt cap $428 M

Cross Country Healthcare surged 29.48% following announcement of an all-cash acquisition by Knox Lane valued at $437 million, disclosed on May 6, 2026. The deal news directly drove the stock's sharp gain.

On May 6, 2026, Cross Country Healthcare announced it had agreed to be acquired by Knox Lane in an all-cash transaction valued at $437 million. This represents a significant M&A event that typically triggers immediate upside revaluation as the market reprices the equity to the deal consideration. The stock's closing price of $13.09 on May 7 reflects the market absorbing this acquisition news. The company also reported Q1 2026 financial results on May 7, but the headline focus and timing of the 29% move align squarely with the acquisition announcement. M&A deals, especially all-cash offers, are among the most concrete catalysts for single-day stock movements of this magnitude, as they establish a known exit value for shareholders.

ERNA

Ernexa Therapeutics Inc.Healthcare

$7.82+$1.78

+29.5%

NASDAQ · Mkt cap $5.2 M

Ernexa Therapeutics surged 29.47% following disclosure of preclinical data showing ERNA-101 achieved 100% survival and complete tumor clearance in ovarian cancer models, a significant milestone for the cell therapy candidate.

The company announced landmark preclinical results on May 6, 2026, demonstrating that its ERNA-101 cell therapy achieved complete tumor elimination and long-term survival in ovarian cancer models when combined with PD-1 blockade. Both headlines describe this as breakthrough or game-changing data that positions the candidate as a potential major catalyst for future clinical development and shareholder value. For early-stage biotech firms, strong preclinical efficacy results in validated models can justify substantial single-day moves, particularly when the indication (ovarian cancer) and mechanism (combination immunotherapy) address material unmet needs. The timing and framing as a landmark milestone likely drove institutional and retail interest. This represents a clear catalytic event tied directly to the company's pipeline progress.

LCUT

Lifetime Brands, Inc.Consumer Cyclical

$7.19+$1.62

+29.1%

NASDAQ · Mkt cap $228 M

Lifetime Brands reported Q1 2026 earnings and revenue that both beat analyst estimates by a large margin (earnings +123%, revenue +3.8%), triggering the 29% gain as a strong operational beat and positive outlook surprise.

Lifetime Brands released first quarter 2026 financial results on May 7, 2026, with both net sales and earnings exceeding consensus expectations. The earnings surprise of 122.86% was particularly dramatic, suggesting the market had underestimated profitability or the company delivered an unexpectedly strong operational performance. The revenue beat of 3.80%, while more modest, still indicates execution above guidance. The stock's 29% single-day jump is proportional to the magnitude of the earnings surprise and suggests investor repricing based on improved confidence in the company's profitability and forward trajectory. The earnings call transcript and summary were released the same day, providing supporting detail to the headline figures.

BOBS

Bob's Discount Furniture, Inc.Consumer Cyclical

$12.67+$2.82

+28.6%

NYSE · Mkt cap $2.1 B

Bob's Discount Furniture reported first-quarter earnings on May 7 showing net revenue growth of 8.5% to $578.1 million and net income of $41 million, driven by new store openings, triggering a sharp 28.63% single-day rally after the stock had traded under pressure at $10.03 just two days prior.

The company released its 1Q 2026 financial results on May 7, the same day of the stock's 28.63% jump. The headlines confirm net revenue increased 8.5% year-over-year to $578.1 million and net income rose modestly to $41 million from $38.6 million in the prior year quarter, with growth attributed to new store expansion. The timing of the earnings release directly aligns with the intraday surge. Context from a May 5 headline indicates the stock had been under recent pressure, trading at $10.03, suggesting investors may have been positioned defensively or had lowered expectations. The earnings beat or positive revision of guidance relative to depressed sentiment appears to have triggered covering and fresh buying. The magnitude of the move suggests the market may have been more bearish on the furniture retail sector or this company specifically heading into earnings, making the results appear more encouraging by comparison.

FABC

StableX Technologies, Inc.Consumer Cyclical

$4.81+$1.07

+28.6%

NASDAQ · Mkt cap $18 M

Fabric.AI announced a strategic partnership with Kopin Corporation to develop MicroLED optical interconnect chips, including the appointment of an industry veteran to lead the program and signed NDAs with major chipmakers, signaling validation and commercial traction in a high-growth AI hardware …

The news headline indicates Fabric.AI (FABC) secured a meaningful partnership with established chipmaker Kopin Corporation to develop Neural I/O MicroLED optical interconnect technology. The announcement highlights three concrete elements: appointment of Bill Maffucci as program lead, signed non-disclosure agreements with two major unnamed chipmakers, and characterization of "accelerated industry interest" in MicroLED-based optical interconnects. For a small-cap AI hardware company, this type of announcement—combining executive talent, NDA commitments from tier-one partners, and explicit reference to growing market demand—typically signals de-risking of a key product pathway and validation from established industry players. The 28.6% single-day gain aligns with investor interpretation of this as a material partnership milestone rather than routine corporate news.

NXTS

N2OFF, Inc.Basic Materials

$5.85+$1.29

+28.3%

NASDAQ · Mkt cap $117 K

No news headlines were published about NXTS in the last 48 hours, so the 28% gain likely stems from a technical bounce, delayed market reaction to an older catalyst, or untracked rumor activity.

The absence of recent headlines makes it impossible to tie the 28.29% single-day jump to a specific corporate event. N2OFF is a microcap stock (trading at $5.85 and ranked 26 for the day's gainers), which means it is typically more susceptible to technical rebounds after sharp prior declines, short covering, retail interest driven by untracked social media or bulletin boards, or delayed price discovery on earnings or news released outside the 48-hour window captured here. Without access to intraday volume, recent technical levels, short interest data, or news from earlier in the week, we cannot distinguish between a fundamental catalyst and pure momentum or technicals. Microcaps in this price range frequently exhibit volatile swings on minimal volume.

SITM

SiTime CorporationTechnology

$797.31+$173.98

+27.9%

PIII

P3 Health Partners Inc.Healthcare

$3.58+$0.72

+25.2%

NASDAQ · Mkt cap $1.8 B

No relevant news headlines appeared in the last 48 hours, so the 25% gain likely reflects either a delayed market reaction to an untracked event, technical momentum in a low-priced healthcare stock, or sector-wide movement in physician services companies.

The absence of recent news headlines makes it impossible to identify a specific catalyst for PIII's sharp 25% intraday gain. P3 Health Partners is a physician-led healthcare services company, and stocks in this category can be sensitive to several typical drivers: earnings surprises or guidance beats that may not appear immediately in broad news feeds, short-covering or technical breakouts in lower-priced equities, shifts in healthcare policy or reimbursement sentiment, or momentum trading in smaller-cap healthcare names. The stock's relatively modest price point ($3.58) also suggests it may be more susceptible to retail trading activity or technical factors. Without headline support, any explanation remains speculative.

ACVA

ACV Auctions Inc.Consumer Cyclical

$6.50+$1.28

+24.5%

NYSE · Mkt cap $1.1 B

ACV Auctions beat Q1 earnings and revenue estimates on May 6, reporting a 92.31% earnings surprise and 11.8% year-over-year revenue growth to $204.2 million, followed by a product enhancement announcement on May 7, driving the 24.52% gain.

The stock's sharp climb aligns directly with earnings results released on May 6 that substantially exceeded analyst expectations. ACV reported a 92.31% earnings beat and 1.37% revenue beat for Q1 2026, with sales reaching $204.2 million, up 11.8% year-over-year. Management also highlighted strong performance in Transport and Capital segments plus growing adoption of value-added dealer solutions despite a challenging wholesale market affected by severe weather. The following day, ACV announced enhancements to its ACV MAX inventory intelligence platform, further reinforcing positive momentum and forward-looking product development. The combination of a large earnings surprise, revenue growth acceleration, and a same-week product announcement likely drove institutional and retail buying interest, propelling ACVA into the top 30 gainers.

ASPN

Aspen Aerogels, Inc.Basic Materials

$5.12+$1.00

+24.3%

NYSE · Mkt cap $452 M

Aspen Aerogels surged 24.27% after reporting Q1 2026 results with revenue that beat estimates by 3.63%, despite an earnings miss, alongside positive guidance including a staged restart of its East Providence manufacturing facility in May and a new subsea pipeline contract award.

The company reported mixed financial results on May 7: it missed earnings estimates by 3.70% but topped revenue expectations by 3.63%, a pattern that often signals operational momentum despite profitability challenges. More importantly, management commentary highlighted several growth catalysts. The East Providence manufacturing facility, which appears to have faced disruption, is set for staged restart in May, signaling capacity recovery ahead. The company also secured an additional subsea pipeline award, supporting demand in the Energy Industrial segment. Cash position strengthened to $175.6 million from $158.6 million year-end, providing balance sheet flexibility. The 24% gain likely reflects investor optimism about near-term manufacturing recovery, contract wins, and improved revenue trajectory despite near-term profitability pressures.

CLFD

Clearfield, Inc.Technology

$37.49+$7.21

+23.8%

NASDAQ · Mkt cap $379 M

Clearfield reported Q2 fiscal 2026 results with net sales of $34.4 million at the high end of guidance and a 39% increase in order backlog to $31.6 million, likely driving the 23.81% stock surge.

Clearfield delivered earnings results on May 6-7, 2026 that met or exceeded market expectations. The company reported net sales of $34.4 million, positioning at the top of its $32-35 million guidance range, and achieved a 2.20% revenue beat versus estimates. More notably, order backlog surged 39% from year-end 2025 to $31.6 million, signaling strong future demand and business momentum. Although the company posted a net loss of $0.04 per share, this matched guidance expectations. The combination of revenue guidance achievement, significant backlog growth, and earnings-per-share alignment suggests investor confidence in the company's trajectory and revenue visibility into future quarters. This narrative of operational strength and demand momentum appears sufficient to justify the substantial single-day gain.

HRB

H&R Block, Inc.Consumer Cyclical

$36.28+$6.96

+23.7%

NYSE · Mkt cap $6.3 B

H&R Block surged 23.74% after posting Q3 earnings and revenue beats with double-digit EPS growth and raising full-year guidance, while also announcing incremental share repurchases and maintaining market share gains.

The stock's sharp gain is directly tied to the Q3 fiscal 2026 earnings announcement released on May 6-7. The company delivered earnings-per-share and revenue surprises of +5.80% and +2.53% respectively, with revenue up 5.3% year-over-year to $2.40 billion. Management raised fiscal 2026 full-year guidance and announced plans for incremental share repurchases. Additionally, H&R Block maintained its assisted channel market share for the third consecutive year of improvement, signaling competitive strength in a traditionally challenging market. The combination of operational outperformance, forward guidance lift, capital return acceleration, and market share stability created a compelling catalyst that justified a large single-day appreciation. The dividend announcement extending the company's 60-year dividend streak, while noted, appears secondary to the earnings and guidance story.

CMRC

Commerce.com, Inc.Technology

$3.56+$0.68

+23.6%

NASDAQ · Mkt cap $178 M

Commerce.com reported Q1 earnings and revenue that beat Wall Street estimates by 21.84% and 4.55% respectively, with improved profitability and AI-driven commerce momentum, driving a 23.61% single-day gain.

The stock jumped on the heels of a same-day earnings release showing Commerce.com exceeded consensus on both earnings per share and top-line revenue for Q1 2026. The company reported $86.8 million in revenue (up 5% year-over-year), posted a GAAP net income of $3.7 million versus a net loss in the prior year quarter, and grew ARR to $359.8 million. News coverage highlighted improved cash flow, expanded AI-driven commerce ecosystem, and a new embedded payments solution with PayPal. Full-year revenue guidance also beat analyst expectations. The earnings surprise magnitude of 21.84% on the bottom line is substantial enough to explain a 23.6% move, and the profitability inflection from loss to gain is a qualitative positive. No negative news or guidance misses were reported.

WRBY

Warby Parker Inc.Healthcare

$27.20+$5.17

+23.5%

NYSE · Mkt cap $2.9 B

Warby Parker surged 23.47% after reporting Q1 2026 earnings and revenue that beat analyst expectations, with sales up 8.3% year-over-year to $242.4 million.

On May 7, 2026, Warby Parker announced first-quarter results that exceeded Wall Street estimates. The company delivered an earnings surprise of +6.67% and a revenue surprise of +1.28%, with quarterly sales reaching $242.4 million, representing 8.3% year-over-year growth. This beat came despite a UBS analyst note from two days prior that had warned of a "challenging" Q1 outlook driven by adverse weather and consumer spending pressure. The positive earnings surprise appears to have reversed that pessimistic positioning and triggered institutional short covering and retail buying interest. The magnitude of the move (23.47% in a single day) suggests the beat was material enough to shift sentiment meaningfully, particularly if prior guidance had been cautious or if forward guidance improved.

First Advantage CorporationIndustrials

$15.76+$2.96

+23.1%

NASDAQ · Mkt cap $3.6 B

First Advantage delivered a strong Q1 2026 earnings beat with earnings beating by 21.89% and revenue growth of 8.6% year-over-year, alongside a company record, driving the 23% jump in stock price today.

First Advantage reported Q1 2026 results on May 7, 2026 that exceeded market expectations on both earnings and revenue fronts. The company delivered a 21.89% earnings surprise and a 3.03% revenue surprise, with revenues reaching $385.2 million representing 8.6% year-over-year growth. The headlines explicitly reference this as a record quarter for the company. Additionally, one headline references "an AI stock" that "broke a company record," suggesting the market may be attributing part of the outperformance to artificial intelligence initiatives or capabilities. The company also reaffirmed full-year 2026 guidance, which typically signals management confidence. The combination of a significant earnings beat, revenue growth, a company record, and maintained guidance appears sufficient to explain the substantial 23% single-day gain.

SGHT

Sight Sciences, Inc.Healthcare

$5.29+$0.99

+23.0%

NASDAQ · Mkt cap $467 M

Sight Sciences reported Q1 2026 earnings on May 6 that beat revenue estimates by 6.06%, returned to double-digit revenue growth, and prompted management to raise full-year 2026 revenue guidance, driving the 23% gain.

The headline evidence points directly to an earnings catalyst. SGHT delivered a positive earnings surprise of 14.30% and a revenue beat of 6.06% for Q1 2026, ended March 31. Management characterized the quarter as a strong start marked by return to double-digit revenue growth and steady gross margins. The company also raised its full-year 2026 revenue guidance during the earnings call. These three factors—the revenue beat, the narrative of resumed growth momentum, and the lifted outlook—are classic drivers of post-earnings rallies, particularly for small-cap medical device and eyecare companies where growth inflection often commands multiple expansion. The timing of the news release on May 6 evening and the subsequent +23% move on May 7 aligns with typical post-earnings trading patterns.

NITO

N2OFF, Inc.Basic Materials

$5.58+$1.02

+22.3%

NASDAQ · Mkt cap $2.9 M

No news headlines were found in the last 48 hours, so the 22% gain on NITO cannot be attributed to a specific announced event. The move likely reflects technical buying, short covering, or an untracked catalyst in a small-cap stock.

The absence of recent news headlines is notable given NITO's substantial single-day gain of 22.26%, ranking it 37 among daily gainers. For a small-cap NASDAQ stock with limited news flow, price moves of this magnitude often stem from technical factors rather than fundamental catalysts. Possible explanations include short covering in a thinly traded security, algorithmic or momentum-driven buying following a recent breakout, or an announcement that has not yet propagated through major news feeds. Additionally, micro-cap and penny stocks are susceptible to retail investor coordination or broker-facilitated buying programs that may not generate immediate press coverage. Without access to intraday order flow, option activity, or social media sentiment data, attributing the move to any specific cause remains speculative.

NTHI

Neonc Technologies Holdings, Inc.Healthcare

$6.49+$1.18

+22.2%

NASDAQ · Mkt cap $120 M

No headlines were found in the last 48 hours to explain NTHI's 22% gain, so the catalyst remains unknown; the move may reflect delayed news dissemination, technical factors, or an untracked corporate event.

Yahoo Finance returned zero news headlines for NTHI in the last 48 hours despite the stock ranking as the 38th biggest gainer on the day with a sharp 22% jump. This absence of corroborating news is striking and suggests either that the catalyst was not picked up by major news feeds, that the move is driven by technical or sentiment factors rather than fundamental news, or that an announcement occurred through a non-traditional channel. Small-cap stocks like NTHI (trading at $6.49) are sometimes subject to momentum trades, short covering, or retail attention spikes that may not align with traditional news cycles. Without headlines, we cannot determine whether the move reflects earnings, guidance, a capital raise, a partnership, insider trading activity, or pure technical action. The lack of news coverage is itself informative but insufficient to identify the specific cause.

Neptune Insurance Holdings Inc.Financial Services

$30.47+$5.49

+22.0%

NYSE · Mkt cap $4.6 B

Neptune Insurance surpassed 300,000 policies and $400M in premium while receiving a tailwind from a FEMA Review Council report urging growth of the private flood insurance market, directly validating the company's core business model and market opportunity.

Two pieces of news arrived within 24 hours that align strongly with investor thesis for Neptune Insurance. First, the company announced it crossed 300,000 policies in force and $400 million in premium, demonstrating rapid scale-up in the private flood insurance space. Second, a FEMA Review Council report to the President explicitly urged growth of the private market for flood insurance, which directly benefits Neptune's addressable market and potentially accelerates adoption. The combination of these announcements—one showing execution, one showing favorable regulatory tailwinds—likely triggered the sharp 22% rally. The timing and messaging suggest institutional recognition that Neptune is positioned to capture significant market share as the private flood insurance sector grows with government endorsement. No earnings surprise or specific new contract was named, but the momentum catalysts are clear and mutually reinforcing.

APYX

Apyx Medical CorporationHealthcare

$3.56+$0.64

+21.9%

NASDAQ · Mkt cap $133 M

Apyx Medical jumped 22% on Q1 earnings that beat revenue estimates by 6.23%, raised full-year guidance to $59–60 million, and showed 36% growth in its Surgical Aesthetics segment, followed by a NewBeauty Award for its Renuvion platform.

The stock's strong move appears driven by better-than-expected financial results announced on May 7th morning. Q1 revenue of $12.5 million exceeded consensus, and management raised 2026 full-year guidance substantially, signaling confidence in accelerating growth. The Surgical Aesthetics business—anchored by the minimally invasive Renuvion platform—delivered the growth driver, posting 36% year-over-year expansion. The same day, an industry award recognition for Renuvion reinforced the narrative around market traction. Together, these signals suggest the company is gaining momentum in a niche but growing aesthetic medicine market. The jump to rank 40 biggest gainer reflects institutional and retail relief that the turnaround story is executing as hoped, though the stock remains well below analyst fair-value targets of $6.40 and street targets around $6.

ELA

Envela CorporationConsumer Cyclical

$23.27+$4.08

+21.3%

AMEX · Mkt cap $411 M

Envela crushed Q1 earnings and revenue estimates by 161.54% and 63.40% respectively, announced on May 6, triggering a 21.26% jump as investors repriced the stock upward on the strong beat.

The news headlines establish that Envela reported first quarter 2026 results on May 6, 2026, well ahead of consensus expectations. The company delivered quarterly revenue of $98.4 million and posted earnings that beat analyst estimates by over 160 percent, while revenue came in 63 percent above expectations. For a small-cap stock trading on AMEX, such a material earnings surprise typically drives significant single-day repricing as investors reassess growth prospects and profitability. The magnitude of the surprise, particularly the outsized earnings beat, suggests either substantially stronger operational performance, favorable one-time items, or a major shift in the company's trajectory relative to prior guidance or consensus models.

LFST

LifeStance Health Group, Inc.Healthcare

$8.85+$1.49

+20.2%

FTNT

Fortinet, Inc.Technology

$107.97+$18.02

+20.0%

NASDAQ · Mkt cap $115 B

Fortinet reported Q1 2026 earnings and revenue that beat Wall Street expectations on May 6, raised full-year guidance, and demonstrated strong demand in AI security and data center markets, driving a 20% single-day gain.

Fortinet announced first-quarter results on May 6 with revenue of $1.85 billion (20% year-over-year growth) and net income of $534.5 million, both exceeding consensus. The company simultaneously raised its full-year outlook, citing strong enterprise demand across AI security, SASE, and OT markets. Analysts highlighted two specific growth drivers: AI ransomware protection and data center security wins, addressing investor concerns about whether cybersecurity demand could sustain momentum in an AI-heavy market. BTIG upgraded the stock on the strength of the quarter. The combination of an earnings beat, guidance raise, and analyst upgrade on a relevant growth narrative (AI-driven security demand) directly explains the magnitude of the move. This is a textbook positive earnings surprise in a cyclical security software category where forward guidance carries substantial weight.

AKAN

Akanda Corp.Healthcare

$37.19+$6.19

+20.0%

NASDAQ · Mkt cap $2.6 M

No news headlines were found in the last 48 hours, so the 19.97% jump in AKAN cannot be directly attributed to a disclosed catalyst. The move likely reflects either technical buying, sector rotation, delayed market reaction to earlier news, or undisclosed market developments.

The absence of recent news headlines for Akanda Corp. on a day when the stock ranked 44th among gainers creates a gap between the magnitude of the move and observable catalysts. For a cannabis-focused specialty pharmaceutical company like AKAN, typical drivers include FDA approvals, licensing agreements, clinical trial results, or shifts in regulatory sentiment around cannabis products. Without headline evidence, this move could reflect several scenarios: a technical bounce after oversold conditions, sector-wide momentum in cannabis or pharmaceutical stocks, delayed market reaction to news released before the 48-hour window, or undisclosed corporate activity. Retail interest or short-covering could also amplify moves in lower-volume securities. Without explicit news, attribution remains speculative.

OIO

OIO GroupIndustrials

$2.13+$0.35

+19.7%

NASDAQ · Mkt cap $679 M

No news headlines were found in the last 48 hours for OIO Group, so the 19.66% gain likely reflects a technical bounce, short-covering, sector rotation, or undisclosed catalyst that Yahoo Finance did not capture.

The absence of any recent news headlines makes it impossible to pinpoint a specific catalyst for OIO's nearly 20% intraday jump. This is a common challenge with lower-liquidity or smaller-cap NASDAQ stocks, where material moves can occur without immediate press coverage or RSS feed distribution. Possible explanations fall into a few generic buckets: technical rebound after prior weakness, short squeeze or retail buying momentum, sector-wide tailwind in OIO's industry, delayed announcement of earnings or corporate event not yet indexed by news aggregators, or insider confidence signaling. Without knowing OIO's sector, float structure, or short interest, we cannot rule in or out any of these mechanisms. The stock's rank as the 45th biggest gainer suggests material conviction behind the move, but volume and volatility data would be needed to distinguish between noise and signal.

LICN

Lichen International LimitedIndustrials

$5.94+$0.96

+19.3%

NASDAQ · Mkt cap $21 M

No news headlines were found in the last 48 hours for LICN, so the 19.28% gain likely reflects a technical rebound, delayed market reaction to an older event, or unconfirmed rumors that have not yet appeared in major financial media.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for LICN's significant 19.28% single-day gain. For a small-cap stock trading at $5.94, possible explanations include a technical oversold bounce if the stock had declined sharply in preceding days, a delayed market reaction to news that has not yet been widely syndicated by major financial outlets, insider buying or accumulation by institutional investors, sector rotation favoring the security's industry, or unconfirmed rumors circulating on social media or message boards. Without access to intraday volume data, after-hours trading activity, or company announcements released through official channels but not yet picked up by Yahoo Finance RSS feeds, it is not possible to distinguish between these scenarios. The lack of news does not rule out a material event occurring that day; it only indicates that major financial media had not yet reported it as of the snapshot date.

PTRN

Pattern Group Inc. Series A Common StockConsumer Cyclical

$16.95+$2.70

+18.9%

NASDAQ · Mkt cap $4.1 B

Pattern Group reported record Q1 2026 results with 43% revenue growth to $774M and a net revenue retention of 127%, directly explaining the nearly 19% stock gain on strong business momentum.

Pattern delivered a headline earnings beat with record first-quarter performance. The two most material metrics are revenue of $774M, up 43% year-over-year, and net revenue retention of 127%, a significant improvement from 115% in the prior year. NRR above 100% indicates the company is expanding within its existing customer base, a sign of product-market fit and customer satisfaction. The earnings call highlighted strong international growth and success in non-Amazon channels, suggesting diversification beyond a single customer concentration risk. These are the types of operational metrics that drive sustained investor confidence in a SaaS or marketplace services business, warranting the substantial single-day gain. The stock's ranking as the 47th biggest gainer indicates broad market participation in the move, consistent with a positive earnings surprise rather than isolated or speculative trading.

ATGL

Alpha Technology Group LimitedTechnology

$19.14+$3.04

+18.9%

NASDAQ · Mkt cap $115 M

No news headlines were found in the last 48 hours for ATGL, so the 18.88% gain cannot be attributed to a specific announced catalyst; this type of jump in a micro-cap stock typically reflects either technical buying, retail momentum, or an untracked news event.

The absence of any Yahoo Finance RSS headlines in the 48 hours preceding this substantial one-day gain makes it impossible to point to a specific fundamental catalyst such as earnings, product announcements, or guidance changes. When a stock ranks in the top 50 daily gainers without corresponding news coverage, the move is likely driven by one of several mechanisms: technical breakout or short covering in a lower-volume security, retail investor interest potentially amplified by social media discussion not yet captured in mainstream financial news feeds, delayed or pre-market announcement not yet indexed, or simple sentiment shift tied to sector momentum. Without access to pre-market filings, SEC Form 8-K submissions, or real-time news sources beyond the RSS feed provided, we cannot isolate the specific trigger, only note that the magnitude of movement suggests something moved market participants despite the absence of tracked headlines.

OSRH

OSR Holdings, Inc.Healthcare

$0.69+$0.11

+18.3%

NASDAQ · Mkt cap $21 M

OSR Holdings announced it will present at the Emerging Growth Conference on May 7, 2026, which likely drove modest investor interest and a modest rebound from what appears to be a deeply depressed stock price.

The only news provided is that OSR Holdings is scheduled to present at the 92nd Emerging Growth Conference on May 7, 2026. This is a micro-cap exposure event rather than a material business announcement, earnings report, or strategic initiative. For a stock trading at $0.69 with an 18.34% daily gain, the conference presentation alone is unlikely to be a sufficient explanation for the move. Small-cap and penny stocks often respond to conference participation, investor presentation schedules, or simply renewed attention from retail traders. Alternatively, the gain could reflect a short squeeze, delayed reaction to unrelated news, or routine volatility typical of low-priced securities where absolute dollar moves are small.

IONZ

Daily Target 2X Short IONQ ETF

$5.46+$0.84

+18.2%

NASDAQ

No news headlines are available, but IONZ is a 2X short leveraged ETF on IonQ; the +18% gain likely reflects a sharp decline in the underlying IONQ stock, which the inverse position amplifies.

IONZ is designed to move inversely to IonQ Inc. with 2X daily leverage, meaning it gains when IonQ falls and losses when it rises. The substantial +18% one-day gain strongly suggests IONQ experienced a significant decline. Without news headlines available, the specific catalyst for IonQ's drop is unknown. However, quantum computing stocks are highly sensitive to regulatory commentary, earnings disappointments, competitive developments, or shifts in investor risk appetite. The size of this move—large enough to rank in the top 50 gainers—indicates either a material negative event at IonQ or a broader market repricing of the quantum computing sector. The absence of news coverage in the RSS feed over 48 hours could reflect a timing lag, delayed headline indexing, or an intraday technical event.

Biggest Losers

Thu, May 7, 2026 50

GDC

GD Culture Group LimitedCommunication Services

$0.15−$1.09

-87.8%

NASDAQ · Mkt cap $7.8 M

GDC announced formation of a special committee to evaluate a going-private proposal on May 6, triggering an 87.82% stock collapse the following day as the market repriced risk around a potential delisting and loss of public market liquidity.

The headline explicitly states that GD Culture Group's board formed a special committee to evaluate a non-binding going-private proposal. This type of announcement typically creates severe uncertainty among public shareholders because a going-private transaction would eliminate public equity ownership, force illiquidity, and usually values shares at a fixed price that may be below market expectations or current trading levels. The massive single-day drop suggests the market interpreted the preliminary proposal as either undervaluing the company, indicating serious distress, or triggering panic selling among retail holders afraid of being locked out. The fact that this is labeled a preliminary non-binding proposal adds further uncertainty about eventual pricing and execution risk, which amplifies downside volatility in micro-cap stocks like GDC.

ENGN

enGene Holdings Inc.Healthcare

$1.72−$7.13

-80.6%

NASDAQ · Mkt cap $114 M

enGene announced updated interim results from its LEGEND pivotal trial on May 7, and the 80% single-day collapse suggests the data fell short of market expectations, likely revealing safety, efficacy, or enrollment shortfalls in this genetic medicine candidate.

enGene is a clinical-stage non-viral genetic medicines company, and the timing of the price drop directly coincides with the release of updated interim results from the LEGEND pivotal cohort trial on May 7. An 80% single-day loss in a biotech stock typically indicates a material negative development in trial data, such as unexpected adverse events, efficacy that missed efficacy thresholds, slower-than-expected enrollment, or unfavorable trial design adjustments. The headline excerpt does not provide detail on the actual results, only that they were announced. For clinical-stage biotech companies with a single or limited pipeline, pivotal trial readouts are make-or-break catalysts. The magnitude of this decline suggests investors interpreted the disclosed data as materially disappointing relative to prior expectations. Without access to the full press release contents, the specific nature of the negative finding cannot be determined from the evidence provided, but the temporal alignment between announcement and the drop is unambiguous.

ONEG

OneConstruction Group LimitedIndustrials

$1.29−$5.27

-80.3%

NASDAQ · Mkt cap $16 M

ONEG collapsed 80% with no headlines in the last 48 hours, making the specific cause unclear; the drop likely stems from a material corporate event, earnings miss, or delisting risk that has not yet surfaced in the available news feed.

No recent news headlines are available to explain this severe one-day decline. An 80% single-day drop is typically driven by a major negative catalyst such as earnings disappointment, guidance slash, insider departures, regulatory action, covenant breach, or delisting warning. For a micro-cap construction services company, common triggers include contract losses, balance sheet deterioration, or cash burn acceleration. The absence of headlines within 48 hours suggests either the news has not yet been widely reported by Yahoo Finance RSS, the market is reacting to delayed information from yesterday or earlier, or insiders have acted on material non-public information. Without access to the company's current SEC filings, press releases, or insider trading data, pinpointing the exact cause is not possible from the evidence provided.

TRDA

Entrada Therapeutics, Inc.Healthcare

$6.85−$9.18

-57.3%

NASDAQ · Mkt cap $285 M

Entrada Therapeutics plunged 57% after announcing Phase 1/2 Duchenne muscular dystrophy trial results that the company claimed as positive but analysts interpreted as disappointing relative to expectations, compounded by a significant revenue miss in Q1 earnings.

On May 7, 2026, Entrada announced topline results from its ELEVATE-44-201 study of ENTR-601-44 in Duchenne muscular dystrophy. The company framed the data as achieving its primary objective with favorable safety, tolerability, and early functional benefit. However, market reaction was sharply negative. Multiple sources indicate analysts found the data fell short of expectations despite the company's framing as a victory. This disconnect between company messaging and market interpretation suggests the efficacy signals or functional benefit metrics did not meet the bar the investment community had priced in. Additionally, Q1 2026 earnings revealed an 86.24% revenue miss versus estimates, indicating commercial challenges or timeline delays. The combination of underwhelming clinical data relative to consensus expectations and weak quarterly revenue created a significant negative catalyst for a clinical-stage biotech company where trial results are the primary valuation driver.

EZGO

EZGO Technologies Ltd.Consumer Cyclical

$0.07−$0.09

-56.9%

NASDAQ · Mkt cap $2.6 M

EZGO dropped 56.94% with no news reported in the last 48 hours, making the cause unclear; the move may reflect delayed market reaction to an untracked announcement, technical selling, or broader sector weakness.

No headlines were found in the last 48 hours to explain EZGO's steep decline, which makes causal attribution difficult. At a stock price of $0.07, EZGO is a micro-cap security where liquidity is typically thin and price moves can be volatile on relatively small volume shifts or forced selling. The magnitude of the drop suggests either a material negative catalyst—such as a missed earnings report, failed trial result, financing setback, or delisting warning—that was not captured by the news source provided, or technical breakdown in an already distressed equity. Micro-cap stocks in this price range are also susceptible to short-term momentum swings and retail investor sentiment shifts that may not be tied to fundamental news. Without access to the company's recent filings, SEC announcements, or broker research, the specific driver remains speculative.

SHFS

SHF Holdings, Inc.Financial Services

$0.46−$0.33

-41.4%

ARAY

Accuray IncorporatedHealthcare

$0.29−$0.18

-38.6%

NASDAQ · Mkt cap $35 M

Accuray withdrew forward guidance and cited geopolitical disruptions and weakness in China during its Q3 2026 earnings call on May 6, prompting the stock to plunge 38.55% the next day.

The earnings headlines from May 6 establish that Accuray reported modest sequential revenue growth but faced material headwinds from geopolitical disruptions and China market pressure, serious enough to trigger a guidance withdrawal. Withdrawing forward guidance is a major negative signal to equity investors, typically interpreted as management's lack of confidence in near-term visibility and often presages continued deterioration. The stock's 38.55% single-day drop is consistent with a sharp loss of confidence following earnings; this magnitude of decline suggests the market had not fully priced in the severity of the guidance withdrawal or the magnitude of China-related headwinds before the call. No specific details on revenue miss or margin compression are provided in the headlines, so the exact nature of the shortfall remains unclear, but the combination of weak guidance and geopolitical/regional risk is sufficient to explain a severe sell-off in a lower-priced equity like ARAY.

FSLY

Fastly, Inc.Technology

$19.50−$12.07

-38.2%

NASDAQ · Mkt cap $3.3 B

Fastly beat Q1 earnings and revenue expectations with record security revenue growth, but investors sold off the stock 38% citing slowing core delivery growth and concerns that AI agentic traffic revenue may not sustain near-term growth rates, causing a rare earnings-beat-driven crash.

Fastly reported record Q1 2026 results with revenues of $173 million, up 19.8% year-over-year, beating estimates by 0.76% and delivering a 62.5% earnings surprise. Security revenues surged 47% to a record $38.8 million. However, the market focused on negative signals: core delivery business growth slowdown and disappointment around AI agentic traffic revenue momentum. Piper Sandler cut its price target from $30 to $27, citing the weak core delivery print, suggesting that investors are concerned about the sustainability of growth and that diversification into security may not be moving fast enough to offset core business deceleration. This represents a classic case where strong headline numbers masked deteriorating unit economics or slowing growth in the company's legacy business, triggering a sharp repricing.

PHOE

Phoenix Asia Holdings Limited Ordinary SharesIndustrials

$19.06−$9.54

-33.4%

NASDAQ · Mkt cap $526 M

Phoenix Asia Holdings fell 33.36% with no news reported in the last 48 hours, suggesting the catalyst was either an untracked announcement, technical breakdown, or market-wide contagion event affecting Asia-focused equities.

No headlines were found in the last 48 hours to explain the sharp 33% decline in PHOE. Without reported news, the move likely stems from one of several possible causes. First, a significant negative announcement may have been released through channels not captured in the Yahoo Finance RSS feed, such as a regulatory filing, SEC disclosure, or company statement made directly to investors. Second, the stock could have experienced a technical capitulation or forced selling triggered by margin calls, options expiration, or index rebalancing. Third, given that Phoenix Asia Holdings is focused on Asia-Pacific markets, regional economic data, geopolitical events, or sector-wide selloffs in Asian equities could have driven the move. Finally, the stock may have been subject to a short squeeze reversal or liquidity event that caused rapid repricing. Without concrete news, attribution remains speculative.

PLNT

Planet Fitness, Inc.Consumer Cyclical

$44.01−$19.95

-31.2%

NYSE · Mkt cap $3.9 B

Planet Fitness crashed 31% after reporting weak Q1 membership sign-ups and slashing full-year revenue and profit guidance, citing bad weather and macro pressures while pausing price hikes.

The headlines establish a clear chain of events. Planet Fitness released Q1 2026 earnings on May 7, and management cut its full-year outlook materially. The core issue cited was weak membership sign-ups during what should be peak enrollment season (January to March), compounded by adverse weather and macroeconomic headwinds. Additionally, the company paused price increases, a key lever for offsetting pressure on membership growth. The market's response of a 31% single-day drop reflects both the earnings miss and forward guidance cut, which together signal deteriorating business momentum. The fitness sector is highly dependent on new customer acquisition during New Year's resolution season, so a miss there is particularly damaging. The fact that management also paused pricing power suggests confidence is low. This is not a broad market decline; the S&P 500 and Nasdaq fell modestly, and a competitor, Peloton, surged the same day, indicating the move is company-specific.

BETR

Better Home & Finance Holding CompanyFinancial Services

$30.52−$12.17

-28.5%

NASDAQ · Mkt cap $248 M

Better Home & Finance reported Q1 earnings that beat revenue estimates but missed on earnings with a loss, and despite management claiming results exceeded guidance, the market reacted sharply negatively to the profitability miss and likely forward guidance or margin concerns.

The news headlines on May 7 show that BETR reported Q1 2026 results with mixed signals: revenue beat estimates by 2.13% and management claimed results exceeded guidance with higher funded loan volume and AI platform expansion. However, the earnings surprise was negative at -19.23%, meaning the company posted a loss worse than expected. This disconnect between top-line beat and bottom-line miss, combined with the magnitude of the stock's decline to rank 11 biggest loser, suggests investors penalized the company heavily for profitability concerns. The loss result likely raises questions about unit economics, whether the loan volume growth is sustainable at scale, or whether guidance for future quarters signals deteriorating margins. Without visibility to the actual guidance revision or forward commentary, the exact nature of investor concern remains partially unclear, but the earnings disappointment clearly triggered the selloff.

SHAK

Shake Shack Inc.Consumer Cyclical

$69.25−$27.27

-28.3%

NYSE · Mkt cap $3.0 B

Shake Shack reported Q1 2026 revenue that missed analyst estimates at $366.7 million, attributed to rising beef costs and inclement weather, triggering the worst day in the stock's history with a 28% plunge.

The headlines establish a clear earnings miss as the primary catalyst. Shake Shack reported first-quarter revenue growth of 14.3% to $366.7 million, which fell short of Wall Street expectations. The company also posted a quarterly profit loss. Multiple sources attribute the miss to specific operational headwinds including elevated beef costs and unfavorable weather conditions. One headline notes the stock is trading at its lowest level in two years. The earnings call transcript shows management cited same-Shack sales growth of 4%, though this appears insufficient to offset margin pressures. Headlines mention potential offsets like World Cup promotions and a new BBQ menu, but these forward-looking initiatives did not prevent the severe selloff. The broader market context shows the S&P 500 and Nasdaq fell from record highs on the same day amid oil price volatility, but SHAK's 28% loss significantly outpaces general market weakness, indicating the earnings miss is the dominant driver.

APAD

A Paradise Acquisition Corp. Class A Ordinary SharesFinancial Services

$8.03−$3.16

-28.2%

CHARR

Charlton Aria Acquisition Corporation

$0.07−$0.03

-27.9%

NASDAQ

No news headlines were found in the last 48 hours, so the 27.90% drop cannot be directly attributed to a publicly disclosed event. CHARR is a SPAC that may be experiencing typical blank-check company volatility.

The absence of recent news makes attribution difficult. Charlton Aria Acquisition Corporation is a special purpose acquisition company (SPAC), a structure that typically exhibits sharp price swings driven by deal announcement timing, investor redemption activity, or market sentiment shifts rather than fundamental business developments. The stock's extremely low price of $0.07 suggests it may be trading below or near its cash trust value, which often triggers selling pressure if sponsors or large holders liquidate positions or if merger negotiations falter. Without a specific headline, the decline could reflect delayed deal progress, margin calls on holders, or simply the seasonal illiquidity and redemption pressures that plague SPACs approaching or after their deadline windows. Technical factors and broader micro-cap market weakness may also play a role.

KALA

KALA BIO, Inc.Healthcare

$0.08−$0.03

-27.8%

IBP

Installed Building Products, Inc.Consumer Cyclical

$216.79−$82.68

-27.6%

NYSE · Mkt cap $6.3 B

IBP shares plunged 27.61% after the company missed Q1 2026 earnings and revenue estimates on May 7, reporting a 14.25% earnings miss and 3.5% year-over-year revenue decline to $660.5 million amid macro headwinds in housing markets.

Installed Building Products reported first-quarter results on May 7 that fell short of Wall Street expectations across multiple metrics. The company delivered earnings 14.25% below estimates and missed revenue expectations despite sales of $660.5 million, down 3.5% year-over-year. The earnings release came amid a period of documented macro pressure on housing sentiment driven by higher Treasury yields and rising mortgage rates, which had already pressured building products stocks in prior trading days. The 27.61% single-day decline reflects both the magnitude of the earnings miss and investor repricing of the company's growth outlook given deteriorating housing market conditions. Initial news reports on May 7 noted an immediate 10.6% drop following the revenue miss announcement, with the additional decline likely occurring as details emerged during the earnings call and investors processed implications for forward guidance and full-year outlook.

AMPX

Amprius Technologies, Inc.Industrials

$16.11−$6.08

-27.4%

NYSE · Mkt cap $1.4 B

Amprius reported Q1 earnings with a net loss despite beating revenue estimates, combined with a warrant-for-common-stock exchange that dilutes existing shareholders, triggering a sharp 27% sell-off on the same day.

On May 6-7, Amprius released Q1 2026 financial results showing a net loss (earnings surprise of -100%) while revenue beat expectations by 11.17%. The company also announced on May 7 that it had agreed with institutional warrant holders to exchange public warrants for common stock, effectively simplifying its capital structure but diluting current shareholders. This two-punch combination—profitability miss combined with dilutive equity restructuring—likely spooked investors who had driven the stock up 8x over the prior year. The timing of the warrant exchange announcement on the same day as earnings intensified negative sentiment. While the revenue beat is positive, the loss and dilution outweighed that benefit in market reaction.

FUTG

Leverage Shares 2x Long FUTU Daily ETF

$9.85−$3.72

-27.4%

NASDAQ

No news headlines are available for the last 48 hours, but FUTG is a 2x leveraged ETF tracking Fintech stocks, so a sharp 27% drop most likely reflects a significant decline in the underlying FUTU stock or broad fintech selloff amplified by the leverage structure.

The absence of any news in the provided headlines makes it impossible to identify a specific catalyst. However, FUTG's structure as a 2x long daily leveraged ETF is directly relevant to interpreting this move. A roughly 13-14% drop in the underlying Fintech ETF or FUTU stock would produce approximately a 27% decline in FUTG due to the 2x leverage multiplier. Leveraged ETFs are designed for short-term tactical trades and can amplify both gains and losses sharply. The move could stem from broad tech or fintech sector weakness, a company-specific news item about Fintech Limited, shifts in interest rate expectations affecting growth stocks, or technical selling. Without headline confirmation, the most likely categories are sector rotation away from fintech or a decline in the underlying security itself, but the precise driver remains unknown.

DRCT

Direct Digital Holdings, Inc.Communication Services

$4.75−$1.76

-27.0%

NASDAQ · Mkt cap $2.0 M

Direct Digital Holdings fell 27% on the day it announced it would report Q1 2026 earnings results, suggesting the market may be reacting to anticipated negative guidance or prior disappointing performance rather than the earnings announcement itself.

The company issued a press release on May 7 announcing that it will report Q1 2026 financial results, but the release does not disclose the actual results, guidance, or any material business updates. The timing of a 27% single-day drop coinciding with an earnings announcement notice is unusual and suggests the market may have negative prior information about the quarter, or the announcement itself contained unfavorable forward guidance buried in the full text not captured in the headline. Alternatively, the drop could reflect broader weakness in digital advertising or ad-tech stocks, sector rotation, or a short-term technical event unrelated to the earnings announcement. A prior positive news item about awards to a subsidiary suggests operational momentum, but this does not override the earnings-related catalyst for such a large move.

PHAR

Pharming Group N.V.Healthcare

$12.00−$4.40

-26.8%

NASDAQ · Mkt cap $834 M

Pharming reported Q1 2026 revenues down 8% year-over-year with RUCONEST revenue falling 15%, likely disappointing investors despite positive pipeline announcements and on-track product expansion plans.

Pharming announced first quarter 2026 financial results alongside clinical presentations at the CIS 2026 meeting. The earnings headline highlights that total revenues fell to $72.4 million, an 8% decline versus Q1 2025, with the company's flagship RUCONEST product experiencing a steeper 15% revenue drop. While management framed the results as "on track" for Joenja pediatric label expansion and international launches in 2026, the absolute revenue declines and the magnitude of the RUCONEST decline appear to have overshadowed the positive pipeline commentary in the market's view. The stock's 26.83% single-day drop suggests investors were either expecting better Q1 performance or interpreted the revenue trends as a warning sign for near-term growth, despite the company's stated confidence in 2026 catalysts.

PAHC

Phibro Animal Health CorporationHealthcare

$43.16−$15.34

-26.2%

NASDAQ · Mkt cap $1.6 B

Phibro reported Q3 earnings that beat revenue and earnings estimates on May 6, yet the stock fell 26% the next day, suggesting the market either found guidance disappointing, anticipated weakness ahead, or reacted to a specific forward-looking concern not detailed in the available headlines.

The headline evidence presents a puzzle. Phibro announced Q3 results on May 6 with revenue up 10.3% year-over-year to $383.5 million, beating estimates by 6.26% and delivering an earnings surprise of 5.92%. These are typically positive catalysts. The company also launched a sustainability platform and announced participation in the Bank of America Securities Health Care Conference. None of these developments appear inherently negative. The 26% single-day drop suggests either the earnings beat masked disappointing forward guidance, margin compression that wasn't flagged in headlines, or a separate material announcement made during or after the earnings call that the available headlines do not capture. Without access to the full earnings call transcript or updated guidance details, the specific trigger remains unclear.

GPGI

GPGI, Inc.Industrials

$12.94−$4.52

-25.9%

NYSE · Mkt cap $4.0 B

GPGI reported Q1 2026 earnings on May 7 with mixed results: CompoSecure delivered record results driven by ROS, but Husky faced unexpected headwinds from oil/resin price shocks and tariff uncertainty, likely triggering the 25.89% sell-off.

The earnings headline reveals a bifurcated story. CompoSecure's record ROS-driven performance and accelerating enterprise deployment are positive signals, while Husky's exposure to commodity price volatility and tariff pressures represents a material near-term headwind. Investors appear to have weighted the Husky weakness more heavily than CompoSecure's upside, suggesting either guidance for Husky was disappointing, margins compressed significantly, or forward guidance reflects ongoing uncertainty in oil and resin markets. The appointment of a Chief Commercial Officer for International on May 6 signals management confidence but does not offset earnings-day disappointment. Without full earnings details and guidance, the precise magnitude of Husky's miss cannot be determined, but the 22nd-largest single-day decline suggests consensus expected better insulation from commodity volatility.

APUS

Apimeds Pharmaceuticals US, IncHealthcare

$1.47−$0.48

-24.6%

AMEX · Mkt cap $6.0 M

Apimeds announced a settlement with Inscobee and a merger with financing on May 5, but the stock fell 24.62% by May 7, suggesting market skepticism about deal terms, dilution concerns from the $100M PIPE, or broader biotech sector weakness unrelated to the headline.

The May 5 announcement described a comprehensive settlement and merger proceeding with a $100 million PIPE financing closing. On its surface this is positive—the company resolved a legal dispute and secured funding to advance its Apitox program through Lōkahi Therapeutics. However, a 24.62% drop two days later is inconsistent with enthusiasm. Likely explanations include: investor concern about PIPE dilution to existing shareholders, unfavorable settlement terms not fully disclosed in the headline snippet, or skepticism about the merger economics and commercial viability of the Apitox program. It is also possible the decline reflects broader biotech sector weakness or short covering that coincided with the announcement rather than a direct negative response to it. The headline excerpt is incomplete, so material terms of the PIPE and settlement are unknown.

SGMO

Sangamo Therapeutics, Inc.Healthcare

$0.10−$0.03

-24.6%

NASDAQ · Mkt cap $31 M

Sangamo Therapeutics fell 24.59% with no news headlines in the last 48 hours, suggesting the drop was driven by technical selling, a delayed market reaction to older news, or investor sentiment shift rather than a fresh corporate announcement.

No news headlines were available in the last 48 hours to directly explain this sharp decline. Sangamo is a clinical-stage gene therapy company with a history of high volatility and dependence on trial results, regulatory decisions, and cash runway concerns. At a stock price of $0.10, the company is extremely small-cap and illiquid, making it susceptible to technical selling, stop-loss cascades, or rebalancing flows. The 24.59% drop could reflect a delayed market reaction to older clinical or financial news not captured in this recent news feed, deteriorating sentiment within the gene therapy sector, capital raising concerns, or simply thin trading mechanics at this price level. Without current headlines, the specific catalyst cannot be identified.

TEAD

Teads Holding Co.Communication Services

$0.87−$0.28

-24.2%

NASDAQ · Mkt cap $61 M

Teads reported first quarter 2026 results on May 7, triggering a 24% sell-off, suggesting the earnings missed expectations or guidance disappointed investors in the digital advertising sector.

The timing strongly implicates the Q1 2026 earnings announcement released this morning as the primary driver of the sharp decline. The press release headline indicates financial results were disclosed, but the summary provided does not include the actual metrics, earnings per share, revenue figures, or forward guidance—all critical details that typically trigger sharp moves. Given Teads' business model as an omnichannel outcomes platform for advertisers, investors likely reacted negatively to either revenue or profitability shortfalls, slowing user adoption, weakening advertiser demand, or reduced guidance relative to market expectations. The company did announce a partnership with Lumen Research the prior day regarding attention science for CTV, which suggests some positive momentum, but this does not appear to have offset concerns raised by the earnings report itself. Without access to the actual financial metrics, the specific nature of the miss cannot be determined with certainty.

AOSL

Alpha and Omega Semiconductor LimitedTechnology

$37.44−$11.89

-24.1%

NASDAQ · Mkt cap $745 M

Alpha and Omega reported Q3 2026 earnings that beat estimates on May 6th, but the 24% drop on May 7th suggests the market viewed guidance, margins, or forward outlook as disappointing despite the earnings surprise.

The headlines confirm AOSL reported Q3 2026 results on May 6th with revenue of $163.8M (up 0.9% sequentially but down 0.5% year-over-year) and delivered earnings and revenue surprises of +16.42% and +2.37% respectively, which normally would be supportive. However, the stock fell 24% the following day, indicating the market's initial positive reaction to the earnings beat was reversed after closer scrutiny of the call, guidance, or margin trends. The earnings summary headlines are incomplete and do not provide forward guidance, profitability detail, or management commentary that would explain such a sharp reversal. The company did announce a new SmartClamp product family on May 7th, but a new product launch would not typically trigger a 24% single-day loss. Sector dynamics (the Nvidia commentary suggesting AI trade rotation away from chipmakers) may have contributed, but the magnitude of the drop is most consistent with disappointing guidance or margin compression disclosed during the earnings call.

INSM

Insmed IncorporatedHealthcare

$104.80−$32.29

-23.6%

NASDAQ · Mkt cap $28 B

Insmed stock tanked 23.55% after reporting Q1 earnings on May 7, primarily driven by disappointing launch performance of its key drug Brinsupri, which missed buy-side expectations despite beating sell-side views.

The headlines establish that Insmed reported Q1 2026 results on May 7, missing revenue estimates by 0.70% while beating earnings expectations by 15.86%. However, the primary catalyst for the 23.55% decline appears to be the commercial performance of Brinsupri, the company's most important new lung drug launch. One analyst headline explicitly states the stock "tanked" due to Brinsupri missing "elevated buy-side expectations," though it beat sell-side consensus. This suggests the market had built higher hopes for the drug's initial uptake than Wall Street's official forecasts reflected, and actual results disappointed those optimistic internal expectations. The company simultaneously launched a patient awareness campaign for bronchiectasis with Ty Pennington on May 6, which may have been an attempt to support the launch, but was insufficient to offset the negative reception to the actual commercial data.

RHLD

Resolute Holdings Management, Inc.Industrials

$107.92−$31.73

-22.7%

NYSE · Mkt cap $1.1 B

Resolute Holdings reported first-quarter 2026 results on May 7, triggering a 22.7% stock collapse, most likely due to disappointing earnings, guidance, or operational metrics disclosed in the earnings announcement.

The timing and magnitude of the decline strongly correlate with the earnings release on May 7 at 11:05 UTC. The stock dropped 22.7% the same day, suggesting the market reacted negatively to Q1 2026 results. Without access to the full earnings statement, the specific driver—whether revenue miss, earnings shortfall, margin contraction, reduced guidance, or commentary on headwinds—cannot be pinpointed. The second headline about CompoSecure's CCO appointment appears unrelated to Resolute Holdings' direct operations and timing, so is unlikely to explain the move. For a management services company like Resolute Holdings, investor sensitivity typically centers on profitability, cash generation, and forward guidance. The magnitude of the decline suggests a material negative surprise rather than a modest miss.

SOAR

Volato Group, Inc.Industrials

$0.20−$0.06

-22.5%

AMEX · Mkt cap $7.8 M

Volato shareholders approved a merger with M2i Global, but the stock fell 22.46% on the news, suggesting market concern about deal terms, dilution, or lack of confidence in the combined entity's value creation.

On May 7, 2026, Volato Group announced that its shareholders overwhelmingly approved the planned merger with M2i Global Inc., an aviation software company. This is nominally positive news—shareholder approval is a necessary step toward closing the deal. However, the stock dropped sharply the same day, ranking as the 29th biggest loser. The disconnect between approval and price decline could reflect several concerns: market skepticism about the acquisition's strategic logic, shareholder dilution from the deal structure, weak near-term financial prospects for the combined entity, or disappointment that the deal was already fully priced in and this merely removes remaining optionality. The headlines confirm the merger approval occurred but do not provide terms, valuation, or management guidance that would explain why the market is selling.

RAIN

Rain Enhancement Technologies Holdco IncIndustrials

$1.46−$0.42

-22.3%

NASDAQ · Mkt cap $10 M

No news headlines were found in the last 48 hours, so the 22% drop cannot be attributed to a specific announced event; the move likely reflects either delayed market reaction to prior news, technical selling, or broader sector pressure.

The absence of any news in the last 48 hours is notable given the magnitude of the decline. Rain Enhancement Technologies Holdco is a small-cap NASDAQ stock with limited analyst coverage and liquidity, which makes it susceptible to sharp moves on light volumes. The drop could stem from several sources: a delayed market reaction to news released earlier than the 48-hour window, profit-taking after a prior rally, exposure to a sector selloff in clean tech or water management, general weakness in speculative small-cap stocks, or an untracked development such as an insider trade filing or social media narrative. Without access to historical price patterns, insider activity, or sector indices for the period, we cannot narrow the cause further.

CSTL

Castle Biosciences, Inc.Healthcare

$19.24−$5.51

-22.3%

NASDAQ · Mkt cap $997 M

Castle Biosciences beat Q1 revenue and earnings estimates on 2026-05-06, but the 22% stock decline suggests investors reacted negatively to forward guidance, margins, or other commentary disclosed during the earnings call rather than the headline results themselves.

The headlines establish that CSTL reported Q1 2026 revenue of $83.7 million, beating estimates by 2.65% and delivering a 12.50% earnings surprise on 2026-05-06. On the surface these are positive results, which creates a puzzle: typically a company that beats both top and bottom-line estimates experiences a stock gain, not a 22% drop. The earnings call summaries provided do not contain specific forward guidance, margin commentary, or management commentary that would explain the reversal. This suggests that during the live earnings call or Q&A session, management made statements regarding profitability trajectory, growth deceleration, competitive pressures, or 2026 guidance that disappointed investors enough to override the beat. Without access to the full call transcript or analyst downgrades issued after the call, the precise catalyst remains partially obscured, though negative forward commentary is the most likely explanation for a same-day selloff following a reported beat.

HOVR

New Horizon Aircraft Ltd.Industrials

$2.20−$0.61

-21.7%

NASDAQ · Mkt cap $132 M

New Horizon Aircraft announced a $20 million equity offering on May 6th, which typically triggers immediate dilution selling and short-term share price declines as investors front-run the issuance.

The headline from May 6th discloses that Horizon Aircraft priced a $20 million offering of common shares. Equity offerings by development-stage or cash-constrained companies commonly provoke sharp single-day sell-offs because they signal dilution to existing shareholders and may indicate the company needed capital urgently. The timing aligns perfectly with the May 7th snapshot showing a 21.71% drop. The second headline announcing an investor webinar for May 7th appears to be a standard follow-up effort to present the offering to potential participants, not a separate negative catalyst. For a micro-cap aerospace company trading on NASDAQ, a $20 million raise represents a material event. Without knowing the offering price relative to the stock's pre-announcement level or the percentage dilution, we cannot quantify the fundamental impact precisely, but the market's reaction is consistent with typical behavior around dilutive equity issuances.

ZTS

Zoetis Inc.Healthcare

$87.31−$23.91

-21.5%

NYSE · Mkt cap $31 B

Zoetis crashed 21.5% after missing Q1 2026 earnings and revenue estimates while slashing full-year guidance due to weak U.S. companion animal sales, sending the stock to a seven-year low.

The earnings miss and guidance cut are definitively established in the headlines. Zoetis reported Q1 earnings that underperformed Wall Street forecasts (earnings miss of 5.09%, revenue miss of 1.66%) with Q1 revenue rising only 1.9% year-over-year to $2.26 billion. More critically, the company cut its full-year 2026 revenue guidance to $9.82 billion at the midpoint, citing weakness in U.S. companion animal sales as the primary driver. Multiple headlines describe the results as "worse than it seems" and characterize the cut guidance as a "heavy lift" for the stock to recover from, explaining investor panic-selling. The broader market decline due to Iran war signals may have added marginal selling pressure, but the earnings-driven collapse is the clear primary catalyst.

VSA

VisionSys AI Inc.Consumer Defensive

$0.53−$0.15

-21.5%

NASDAQ · Mkt cap $9.5 M

No news headlines were available in the last 48 hours to explain the 21.47% drop in VSA stock, so the cause remains unclear from public reporting.

VSA (VisionSys AI Inc.) fell sharply on May 7, 2026, but no news headlines were found in the Yahoo Finance RSS feed for the preceding 48 hours. This disconnect between the significant price decline and lack of visible news creates ambiguity about the catalyst. For a small-cap AI stock trading at $0.53, typical drivers of such moves could include delayed earnings announcements or guidance revisions, insider selling or lock-up expiration events, sector-wide pressure on unprofitable AI firms, short-seller reports, clinical or regulatory setbacks (if the company has biotech-adjacent operations), or technical capitulation in a thinly-traded name. Without headlines, we cannot distinguish between these possibilities based on the evidence at hand. The stock's rank as the 34th biggest loser suggests this was a real liquidation event, not a rounding error, but its cause remains unconfirmed by public information sources.

AMPL

Amplitude, Inc.Technology

$5.91−$1.61

-21.4%

NASDAQ · Mkt cap $1.8 B

Amplitude fell 21% after Bank of America downgraded the stock to Neutral from Buy, citing execution risks tied to its Statsig acquisition and weakening profitability outlook, despite the company beating Q1 revenue estimates.

The headlines establish that Amplitude reported Q1 2026 revenue of $94 million, beating expectations by roughly 1%, with year-over-year growth of 17%. However, the stock initially dropped 11.8% after hours on earnings (May 6), then fell an additional 21.41% by May 7 following the BofA downgrade. The downgrade appears to be the primary catalyst for today's larger decline. The BofA analyst flagged execution risks associated with Statsig, a strategic partnership announced during the earnings call, and signaled concern about deteriorating profitability. The company also reported an earnings surprise of negative 233%, indicating a significant loss in the quarter. While the company expanded its enterprise customer base and announced positive partnerships with firms like Adswerve, the profitability concern and execution risk warning from a major bank appears to have overwhelmed the revenue beat and growth narrative.

GDTC

CytoMed Therapeutics LimitedHealthcare

$0.72−$0.20

-21.4%

NASDAQ · Mkt cap $11 M

No news headlines were found in the last 48 hours, so the 21.39% decline likely reflects either delayed disclosure of a negative corporate event, sector-wide selling pressure, or technical/liquidity factors typical of low-priced biotech stocks.

The absence of any news in the Yahoo Finance RSS feed over the past 48 hours means the headline record does not identify a specific catalyst for the sharp decline. For a small-cap biotech company like CytoMed Therapeutics trading at $0.72, typical drivers of sharp single-day losses include clinical trial setbacks or negative data readouts that may not be immediately picked up by mainstream financial news feeds, regulatory actions, financing dilution announcements, or shifts in sector sentiment toward early-stage therapeutics. The stock's rank as the 36th biggest loser suggests it was not an isolated micro-cap glitch but a material move. Without access to company filings, press releases, or clinical trial databases updated since the snapshot date, the specific cause remains unknown and could also involve reduced trading volume amplifying price moves in a thinly traded security.

AREB

American Rebel Holdings, Inc.Consumer Cyclical

$0.23−$0.06

-21.0%

NASDAQ · Mkt cap $4.8 M

American Rebel Light Beer announced a major distribution partnership with Tootsie's beachfront venue on the same day the stock fell 21%, suggesting the market either anticipated this news and is now profit-taking, or the news fails to offset broader headwinds or investor skepticism about the comp…

The headline describes what appears to be a positive development: American Rebel Light Beer securing a prominent placement at a newly opened beachfront entertainment complex in Panama City Beach operated by the decades-old Tootsie's Orchid Lounge brand. On the surface, expanded distribution channels should support revenue growth. However, the stock declined sharply on the same day the news was released. This mismatch suggests either (1) the news was already priced in or telegraphed to investors before the formal announcement, leading to profit-taking; (2) the market views a single venue placement as insufficient to change the company's trajectory; or (3) there are underlying concerns about American Rebel's financial health, cash burn, or competitive position that overshadow incremental distribution wins. Without earnings data, balance sheet concerns, or insider activity, the precise driver of the sell-off remains ambiguous, though the timing raises questions about whether the announcement itself triggered the decline.

HUBC

HUB Cyber Security Ltd.Technology

$0.26−$0.07

-20.8%

NASDAQ · Mkt cap $23 M

No news headlines were found in the last 48 hours, so the 20.82% decline cannot be directly attributed to a reported event. The drop likely stems from technical selling, broader sector weakness, or undisclosed company developments.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for HUBC's sharp 20.82% decline on May 7, 2026. For a micro-cap cybersecurity stock trading at $0.26, typical drivers of single-day losses include profit-taking after a previous rally, deteriorating technical support levels, sector-wide selloffs in technology or cybersecurity equities, liquidity constraints that amplify price moves on modest volume, or unannounced insider developments that precede formal disclosure. Without access to intraday trading activity, social media sentiment, or broader market context for that date, we cannot distinguish between these scenarios. A stock at this price point is also sensitive to short-selling activity or margin calls, which can create outsized moves independent of fundamental news.

ONT

Onterris, Inc.Industrials

$17.45−$4.55

-20.7%

VITL

Vital Farms, Inc.Consumer Defensive

$9.52−$2.48

-20.7%

NASDAQ · Mkt cap $476 M

Vital Farms reported Q1 revenue that beat expectations by 1.63% with 15.4% year-over-year growth, but posted a net loss and disappointed on full-year guidance, triggering a sharp 20.67% sell-off as investors repriced growth and profitability expectations downward.

On May 7, 2026, Vital Farms announced first-quarter results showing revenue of $187.2 million, which exceeded Wall Street estimates by 1.63% and grew 15.4% year-over-year—a positive signal. However, the earnings surprise was -132.43%, indicating a significant loss for the quarter that fell far short of expectations. The headline mentioning "full-year revenue g..." (text truncated) suggests reduced forward guidance was also provided. In food and beverage companies, investors often weight near-term profitability and forward guidance as heavily as or more heavily than current-quarter revenue beats. A large earnings miss combined with presumed guidance reduction would justify a sharp repricing downward, even if top-line growth remains solid. The magnitude of the drop reflects market disappointment in the company's path to profitability and near-term outlook rather than demand weakness.

BKSY

BlackSky Technology Inc.Industrials

$32.24−$8.27

-20.4%

NYSE · Mkt cap $844 M

BlackSky reported Q1 2026 earnings on May 7 that significantly missed Wall Street expectations, delivering a -120.13% earnings surprise and -26.66% revenue miss, triggering the 20% stock decline.

BlackSky Technology announced first quarter 2026 results on May 7, 2026, and the company fell well short of consensus estimates. The earnings surprise of -120.13% indicates the company reported a larger loss than expected, while the revenue miss of -26.66% shows actual quarterly revenues fell substantially below analyst forecasts. Multiple financial outlets published articles throughout May 7 analyzing these shortfalls against Wall Street estimates. Stonegate Capital Partners also updated coverage on the same day following the earnings release. For a space technology company with ongoing losses and declining revenues relative to expectations, such a significant earnings miss typically triggers sharp repricing, particularly if it raises questions about the path to profitability or the commercial viability of the Gen-3 satellite platform mentioned in the analyst update. The magnitude of the price decline aligns with the severity of the estimate misses reported.

ARMG

Leverage Shares 2x Long ARM Daily ETF

$17.48−$4.47

-20.4%

NASDAQ

No news headlines available for the past 48 hours. The -20.36% drop in this 2x leveraged ARM ETF most likely reflects a sharp decline in the underlying ARM Holdings stock price, which would be amplified by the fund's daily leverage structure.

Zero news headlines were found in the 48-hour window, so there is no direct evidence of a specific catalyst. However, ARMG is a 2x daily leveraged long ETF tracking ARM Holdings, meaning it amplifies both gains and losses of the underlying stock by approximately two times on a daily basis. A roughly 10% drop in ARM itself would translate to approximately a 20% decline in ARMG, matching the observed move. The likely causes are either (a) adverse news or technical selling in ARM that has not yet propagated to the RSS feed captured, (b) broad semiconductor or technology sector weakness, or (c) company-specific developments in ARM's business. Without access to ARM's own price action or news headlines, we cannot determine which scenario occurred.

AKBA

Akebia Therapeutics, Inc.Healthcare

$1.18−$0.30

-20.3%

NASDAQ · Mkt cap $236 M

Akebia reported Q1 earnings that missed revenue estimates by 5.2% and posted a loss, offsetting positive operational highlights like record Vafseo revenue and 60% patient growth, triggering a -20% sell-off.

The earnings release on May 7 presents a mixed picture: executives touted a "strong start to 2026" with record quarterly net product revenue for Vafseo ($15.8 million) and a 60% increase in patients treated, alongside total net product revenues of $52 million. However, the company simultaneously delivered a negative earnings surprise of -125.56% and missed revenue estimates by 5.20%. This disconnect—between operational momentum and bottom-line misses—likely spooked investors who expected the operational gains to translate into financial outperformance. The stock's heavy loss ranking (43 biggest loser) suggests the revenue miss and net loss result weighed more heavily than the positive volume and adoption metrics in market sentiment, particularly for a biotech company where profitability trajectory is critical to valuation.

STEM

Stem, Inc.Utilities

$8.72−$2.20

-20.1%

NYSE · Mkt cap $55 M

Stem reported Q1 2026 earnings on May 6 with a significant revenue miss of 22.04% below estimates, offsetting a modest earnings beat, triggering the 20% stock decline.

Stem announced Q1 2026 results on May 6, 2026, revealing a material revenue shortfall of 22.04% versus analyst expectations. While the company delivered a positive earnings surprise of 9.36%, this appears insufficient to offset investor disappointment over the top-line miss. In energy and technology transition businesses, revenue growth is typically a primary valuation driver, and a miss of this magnitude suggests either demand weakness, project delays, or execution challenges that concern the market. The earnings beat likely reflects cost management rather than operational strength. The timing aligns perfectly with the stock's 20.12% single-day decline on May 7, the day after the earnings announcement.

GTN

Gray Media, Inc.Communication Services

$4.43−$1.10

-19.9%

NYSE · Mkt cap $515 M

Gray Media reported Q1 2026 earnings with a loss and revenue decline year-over-year, missing earnings expectations by 6.25%, which likely triggered the 19.89% sell-off despite revenue beating by 1.19%.

Gray Media announced Q1 2026 results on May 7, 2026, delivering mixed performance. While the company beat revenue estimates by 1.19%, landing at $768 million, it reported a net loss and missed earnings expectations by 6.25%. This earnings miss is the primary catalyst for the sharp decline. Additionally, revenue fell 1.8% year-over-year, indicating contraction in the local television broadcasting business. Though the company announced a quarterly dividend of $0.08 per share and closed an $80 million acquisition of stations from Block Communications, these positive actions were overshadowed by the earnings miss and deteriorating profitability. For media companies with narrow margins, an earnings miss combined with year-over-year revenue decline signals operational challenges and raises investor concerns about forward guidance and cash flow sustainability.

USPH

U.S. Physical Therapy, Inc.Healthcare

$59.00−$14.65

-19.9%

NYSE · Mkt cap $1.2 B

USPH dropped nearly 20% after missing Q1 earnings estimates by 16.67% despite meeting revenue expectations and reporting record revenue, signaling profit margin compression and investor disappointment in profitability despite top-line growth.

The headlines present a mixed picture that likely triggered the selloff. While USPH reported record Q1 revenue of $198.3 million, up 7.9% year-over-year and in line with expectations, the company posted a GAAP loss of $0.12 per share, representing a 16.67% earnings miss versus Wall Street estimates. This disconnect between revenue growth and earnings weakness suggests margin compression or elevated costs that concerned investors. The company did reaffirm full-year guidance, which may have prevented a deeper decline, but the earnings disappointment was severe enough to outweigh the revenue beat and record top-line result. The market appears to have punished the bottom-line miss more heavily than rewarding the revenue performance, a common pattern when profitability deteriorates despite sales growth in healthcare services businesses.

CTRI

Centuri Holdings, Inc.Utilities

$33.56−$8.24

-19.7%

NYSE · Mkt cap $2.1 B

Centuri reported Q1 earnings that beat revenue estimates by 19% and achieved record backlog of $6.5 billion with 76% gross profit growth, yet the stock fell 19.7%, suggesting the market either expected significantly stronger results or has concerns about future execution or margins despite the st…

The headline news appears superficially positive: Centuri delivered a revenue beat, achieved record backlog, and demonstrated substantial gross profit growth year-over-year. However, the headline also explicitly states the company "reports Q1 loss," indicating the firm was unprofitable despite revenue and gross profit growth. The market's 19.7% sell-off suggests investors may have found the bottom-line loss disappointing relative to expectations, or the forward guidance or commentary during the earnings call raised concerns about profitability trajectory, working capital, or execution risks on that large backlog. Without access to full earnings details, guidance statements, or management commentary, the exact trigger remains somewhat opaque, but the disconnect between positive operational metrics and negative stock reaction points toward profitability concerns or lowered forward expectations.

OKLL

Daily Target 2X Long OKLO ETF

$10.82−$2.63

-19.6%

NASDAQ

No news headlines were found in the last 48 hours, but OKLL is a 2X leveraged long ETF tracking OKLO (small-cap nuclear energy), so a 19.55% drop likely reflects an approximately 10% decline in the underlying OKLO stock, possibly driven by broad energy sector weakness, individual company news aff…

Without recent headlines, we cannot identify a specific catalyst. However, OKLL's structure as a daily target 2X leveraged long ETF means its price movements are mechanically amplified versions of its underlying asset OKLO. A roughly 10% move in OKLO would produce approximately this 19-20% move in OKLL. The most likely causes for such a move in a small-cap nuclear energy stock are sector-wide weakness in renewables or nuclear energy, company-specific news not yet reflected in the headline feed, negative commentary from analysts or competitors, deterioration in energy commodity prices, or a broader market deleveraging event that hit small-cap growth stocks disproportionately. Without access to OKLO-specific developments or broader market context from May 7, 2026, we cannot distinguish among these possibilities.

MasterBeef GroupConsumer Cyclical

$6.65−$1.60

-19.4%

NASDAQ · Mkt cap $92 M

No news headlines were found in the last 48 hours to explain MB's 19.39% decline, so the cause remains unclear without additional context on company-specific events or broader market conditions.

The absence of any recent news headlines makes it impossible to pinpoint a specific catalyst for MasterBeef Group's sharp 19.39% drop on May 7, 2026. Without access to company announcements, earnings releases, regulatory actions, or other material events, we cannot determine whether this decline stems from negative news that hasn't yet been indexed by Yahoo Finance RSS, technical selling pressure, broad sector weakness, or an undisclosed corporate development. For a relatively small-cap NASDAQ stock like MB trading at $6.65, the move could also reflect lower liquidity amplifying intraday volatility. Any hypothesis at this point would be speculation.

BUUU

BUUU Group Limited Class A Ordinary ShareIndustrials

$18.38−$4.42

-19.4%

NASDAQ · Mkt cap $474 M

No news headlines were found in the last 48 hours to explain BUUU's steep 19.39% drop, so the cause remains unknown based on available evidence.

Despite the significant single-day loss ranking BUUU as the 50th biggest loser on NASDAQ, no recent news headlines from Yahoo Finance RSS were available to establish a concrete cause. This absence of reported news is itself notable; a 19% drop typically correlates with material corporate announcements such as earnings misses, guidance reductions, insider selling disclosures, regulatory actions, or broader sector selloffs. Without access to intraday press releases, SEC filings, or social media-driven events, the driver cannot be determined from the provided data. Possible categories include delayed earnings releases, unexpected restructuring announcements, technical selling, options expiration effects, or untracked microeap volatility, but these remain speculative.